期刊
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
卷 55, 期 3, 页码 404-410出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0b013e3181e73f4b
关键词
antiretroviral therapy; CD4 lymphocyte count; HIV; pregnancy; prevention of mother to child transmission
资金
- Bill and Melinda Gates Foundation
- William and Flora Hewlett Foundation
- Robert Wood Johnson Foundation
- Henry J. Kaiser Family Foundation
- John D. and Catherine T. MacArthur Foundation
- David and Lucile Packard Foundation
- Rockefeller Foundation
- Starr Foundation
Objective: Identifying antiretroviral therapy (ART) eligible HIV-infected (HIV+) pregnant women and rapidly initiating treatment preserves maternal health and prevents mother-to-child transmission. However, there have been few investigations of the performance of ART eligibility criteria in pregnant and postpartum women in resource-limited settings. Methods: Pregnant and recently postpartum HIV+ women received CD4(+) cell count and World Health Organization (WHO) clinical staging at enrollment into the mother-to-child transmission Plus Initiative. We compared immunologic and clinical criteria based on 2009 WHO ART treatment guidelines (WHO stage 3/4 or CD4(+) cell count <= 350 cells/mm(3)) in identifying ART eligible women. Results: Among 6036 women (62% antepartum, 38% postpartum), 2915 (48%) were ART eligible. Only 23% had WHO stage 3 or 4 disease, whereas 94% met CD4(+) cell count criterion. Among 5356 women with WHO stage 1 or 2 disease, 2235 (42%) had CD4(+) <= 350 cells per cubic millimeter. Change of CD4(+) cell count ART eligibility threshold from <= 200 to <= 350 cells per cubic millimeter increased the proportion of ART eligible women from 21% to 45%. Conclusions: Use of CD4(+) cell count criterion is superior to clinical staging in identifying pregnant and postpartum HIV+ women eligible for ART. Improving access to CD4(+) testing is essential to identify and treat eligible women, optimizing maternal and child health outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据